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Background: Serum antibody to influenza can be used to identify past exposure and 
measure current immune status. The two most common methods for measuring this 
are the hemagglutination inhibition assay (HI) and the viral neutralization assay (NT), 
which have not been systematically compared for a large number of influenza viruses.
Methods: A total of 151 study participants from near Guangzhou, China, were enrolled 
in 2009 and provided serum. HI and NT assays were performed for 12 historic and 
recently circulating strains of seasonal influenza A. We compared titers using Spear-
man correlation and fit models to predict NT using HI results.
Results: We observed high positive mean correlation between HI and NT assays 
(Spearman’s rank correlation, ρ=.86) across all strains. Correlation was highest within 
subtypes and within close proximity in time. Overall, an HI=20 corresponded to 
NT=10, and HI=40 corresponded to NT=20. Linear regression of log(NT) on log(HI) 
was statistically significant, with age modifying this relationship. Strain- specific area 
under a curve (AUC) indicated good accuracy (>80%) for predicting NT with HI.
Conclusions: While we found high overall correspondence of titers between NT and 
HI assays for seasonal influenza A, no exact equivalence between assays could be 
determined. This was further complicated by correspondence between titers changing 
with age. These findings support generalized comparison of results between assays 
and give further support for use of the hemagglutination inhibition assay over the 
more resource intensive viral neutralization assay for seasonal influenza A, although 
attention should be given to the effect of age on these assays.
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1  | INTRODUCTION
Accurate measurement of individuals’ pathogen exposure history 
is an essential tool for understanding risk factors of infection and 
population- scale patterns of transmission. Determined through a 
variety of methods, the concentration of antibodies in sera is consid-
ered the gold standard method to estimate past exposure to pathogens. 
Two of the most common methods for measuring serum antibody to 
influenza are the hemagglutination inhibition (HI) and virus neutraliza-
tion (NT) assays.1 Although both tests serve as measures of antibody 
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concentration in sera, they have important differences in how they are 
conducted and how they measure immunity. The HI test, which is fast 
and relatively easy to perform, is considered to be easily standardized 
and reproducible across laboratories. However, only the effect of anti-
bodies on the hemagglutination process, by which a virus binds to red 
blood cells, is measured with HI, and the endpoint is only a correlate 
of the ability of antibodies to inhibit virus infection of host cells.2,3 In 
contrast, NT assays, also known as microneutralization assays, mea-
sure the titer needed to block the cytopathic effects of the virus, by 
measuring antibodies that block entry of the virus into the cell, inter-
nalization of the virus, and fusion of the HA. Although NT is intuitively 
more appealing because it more closely mirrors the disease process in 
vivo, it is more time- consuming and expensive and considered harder 
to standardize across laboratories.2,3
Despite the widespread usage of these two methods, there have 
been few formal comparative studies of these measures. In a 2007 
study by Stephenson et al., HI and NT tests were performed in 11 lab-
oratories to investigate reproducibility of each assay for detection of 
anti- H3N2 influenza antibodies. They found significantly higher vari-
ation in NT results between laboratories than in HI results, yet better 
discrimination among NT and generally limited correlation between 
the tests.2 In a follow- up study of anti- H1N1pdm antibodies, signif-
icant correlation between HI and NT was found, yet the conversion 
factors between laboratories varied significantly. Furthermore, NT 
titers were both significantly higher and significantly more variable 
than HI titers.3
The difference in reliability between laboratories with these two 
assays is a direct result of how they are measured. Hemagglutination 
inhibition and viral neutralization assays assess the level of functional 
immunity to a virus in a similar manner, both using serial dilution of 
sera applied to a fixed amount of virus to determine at which titer of 
sera the virus is effectively inhibited. The difference is in the biological 
mechanism used as an indicator for inhibition. The HI assay utilizes the 
natural process of viral hemagglutination, a process in which a lattice 
forms by binding of viruses to red blood cells; this process is blocked 
when sufficient antibody with affinity to the virus is present. A serum 
HI titer of ≥40 is assumed to indicate a 50% reduction in susceptibility 
compared with an individual with undetectable titer.4–6 The NT assay, 
in contrast, measures cytopathic effects of the virus, the invading and 
killing of cells, through plaque formation. Again, the antibodies in the 
sample serum are tested for their ability to block this activity. Results 
are expressed as reciprocal of the highest dilution at which virus infec-
tion is blocked.7
The viral neutralization test is valued for its high sensitivity and 
specificity, which have been found to be higher than for microneu-
tralization fluorescent antibody test (MFA) and HI, although some 
have indicated similar sensitivity and specificity between HI and 
NT tests for certain viruses, including influenza A H1N1 2009.2,5,8,9 
Additionally, it has been found to be more strain- specific than HI for 
seasonal and H5N1 viruses, and HI tests have been found to be insen-
sitive for the detection of human antibody responses to avian hemag-
glutinin, especially when intact virus is present.2,6 According to Gross 
and Davis, the neutralization test “appears to detect lower levels of 
viral antibody than does the HI test,” a difference that “may be relat-
ed to the high serum concentrations and the additional viral antigens 
detected by NT.”10 It is, however, a laborious and time- consuming pro-
cedure, making it less suitable for testing large numbers of samples.11 
Disadvantages of NT include its difficulty level and time required to 
perform, the need for live virus, and that technical aspects of the assay 
can affect titers.3,8 However, the major disadvantage of it has been 
poor reproducibility between laboratories.2,3
In addition to low sensitivity, in particular as compared with radio-
immunoassay (RIA) and enzyme- linked immunosorbent assay (ELISA), 
disadvantages of HI include subjectivity of result interpretation and 
reliability issues in relation to freshness of reagents. For both tests, 
immunity measurement is not exact, but rather based on titer cut 
points, and the endpoint of both assays requires visual inspection. 
Other than cost, ease, and reduced variability, a major advantage of 
HI over NT for measurement of seasonal influenza immunity is that 
HI does not require cytopathy, which does not always occur for each 
influenza virus in this assay.7
Hemagglutination inhibition and NT assays have been utilized for 
years to investigate influenza immunity, although only a few studies 
have directly compared the assays’ influenza antibody detection capa-
bilities, and most of these studies evaluated vaccine- derived immuni-
ty.2,3,12 Here, we compare HI and NT antibody titers from a sample 
of individuals from Guangdong Province, China, in order to formally 
compare the performance of HI and NT titers for measuring naturally 
derived immunity to twelve historic and recently circulating strains of 
influenza A. These twelve strains are seasonal influenza strains of both 
H3N2 and H1N1 subtypes that have been or are in broad circulation 
since 1968. Additionally, we will attempt to determine an equivalence 
factor between HI and NT titers for direct translation and comparison 
of results from both assays.
2  | METHODS
2.1 | Sample collection
Sera samples were collected from 151 study participants from ran-
domly selected households in five study locations in a transect extend-
ing to the northeast of Guangzhou, China, from 8 July 2009 to 21 
September 2009, as described in Lessler et al.13 All study participants 
were administered informed consent, and a single blood sample was 
collected in a 5- mL non- heparin containing vacuum tube from each. 
Sera were extracted and split at Guangzhou Hospital, and testing and 
storage were done at Shantou University.
2.2 | Laboratory testing
Hemagglutination inhibition (HI) and neutralization (NT) assays were 
performed for twelve historic and recently circulating strains of influ-
enza A: nine H3N2 strains (A/Hong Kong/1/1968, A/Victoria/3/1975, 
A/Bangkok/1/1979, A/Beijing/353/1989, A/Wuhan/359/1995, A/
Fujian/411/2002, A/Shantou/90/2003, A/Shantou/806/2005, and 
A/Shantou/904/2008), two previous seasonal H1N1 strains (A/
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Shantou/104/2005 and A/Shantou/92/2009), and one 2009 pan-
demic H1N1 strain (A/California/07/2009). Laboratory tests were 
performed as described in Lessler et al.13 In brief, the 50% tissue 
culture infectious dose (TCID50) for each virus was determined on 
Madin- Darby canine kidney (MDCK) cells. The neutralization con-
centration was considered to be the reciprocal of the highest dilu-
tion of sera at which 50% of wells were infected (calculated using 
the method of Reed and Muench).14 Sera were thawed, treated with 
a receptor- destroying enzyme (RDE) to remove non- specific inhibi-
tors, then heat- inactivated at 56°C for 30 minutes. RDE- pre- treated 
sera were absorbed with Turkey red blood cells before being used in 
HI or NT tests, to remove substances causing non- specific aggluti-
nation. Antibody titer was determined by testing serial twofold dilu-
tions from 1:10 to 1:1280 in duplicate, resolving uncertain results 
by additional quadruplicate tests. Positive and negative control sera 
were also tested. HI assay was conducted with 0.5% turkey erythro-
cytes using four hemagglutination units. NT tests were carried out by 
mixing serially diluted sera with 100 TCID50 of MDCK cell- adapted 
viruses of each strain, incubated for 1 hour at 37°C, and added to a 
MDCK cell monolayer. Cytopathic effect was read and hemaggluti-
nation assays performed to detect the presence of viral replication 
3 days after inoculation. The highest dilution with complete protec-
tion of the cell monolayer in >2 quadruplicate wells was considered 
to be the NT titer. Both assays were performed in the same labora-
tory within the same week of each of other by an overlapping study 
team. Samples undergoing each assay were handled and processed 
identically, undergoing same sequence of freezing and thawing before 
testing. The full protocol is described in the WHO Manual on Animal 
Influenza Diagnosis and Surveillance.15
2.3 | Statistical analysis
Hemagglutination inhibition and NT titers were compared using 
Spearman correlation between log2(HI/5) and log2(NT/5) titers on the 
12 reference strains. We refer to titer values as log(HI) and log(NT) for 
the remainder of this manuscript. Cross- correlation between strains 
was calculated by the same method.
We examined the ability of one assay to predict status based 
on the other. We treated detectable NT titers as the gold standard 
(i.e., NT titer ≥20) to calculate receiver operator characteristic (ROC) 
curves using different cutoffs for “positivity” for equivalent HI titers 
to predict status. Linear regression models were fit to predict log(NT) 
titer using log(HI) titer. All statistical analyses were conducted in r 
Statistical Software, version 3.0 (www.cran.org).
3  | RESULTS
One hundred and fifty- one study participants were included in this 
analysis. The median age among them was 45 years (SD=18.75; 
range=7–81), with 7.3% aged <15 years (11/151). In total, 54.3% 
of participants were male (82/151). Among all participants, 66.2% 
(100/151) had never received an influenza vaccination, with only 7 
(4.7%) receiving vaccines during the current or previous year, 6 (4.0%) 
within the last 2- 5 years, and 19 (12.6%) >5 years prior; 19 (12.6%) 
were unsure or unknown.
Antigenic testing of sera from the 151 pilot study participants for 
twelve strains of influenza A virus (shown in Fig. 1) indicated a high 
positive mean correlation between hemagglutination inhibition and 
neutralization assays (Spearman’s rank correlation, ρ=.86), and both 
H3N2- and H1N1- specific correlations were found to be high (ρ=.84; 
ρ=.83) (Fig. 2). Strain- specific correlation varied by year and serotype, 
with the highest correlation observed for A/Fujian/411/2002 (H3N2) 
(ρ=.92) and the lowest observed for A/California/07/2009 (H1N1; 
ρ=.48; Fig. 3). Two strains of H1N1, A/Shantou/92/2009 and A/
California/07/2009, had very low titer results overall (Table 1), result-
ing in low correlation coefficients. For A/Shantou/92/2009, however, 
HI titers appear to be more discriminating at the lower end, which indi-
cates that the HI assay might be more sensitive for this strain than NT 
(Fig. 3). This relationship appears to be common across several strains 
examined (Fig. 3). Correlation of titers from different influenza strains 
using the same assay was highest between strains of the same sub-
type and in close proximity in time (Fig. S2). The highest correlations 
were found between A/Shantou/806/2005 and A/Shantou/90/2003 
F IGURE  1 Neutralization assay (NT) (left) and hemagglutination 
inhibition assay (HI) (right) titers for each of the 151 participants in 
the study plotted by rank of age (oldest at top). Color indicates the 
titer measured by each assay. Strains are indicated on the x- axis of 
each figure
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(ρ=.83) and A/Shantou/806/2005 and A/Shantou/904/2008 (ρ=.82) 
for HI, and between A/Fujian/411/2002 and A/Shantou/90/2003 
(ρ=.88) for NT.
Linear regression of log(NT) on log(HI) values indicated a statisti-
cally significant association between the values. The resulting model 
was log(NT) titer = 0.0007 + 0.9733 log(HI), with β1 P- value <.0001. 
Separate models for H3N2 and H1N1 were nearly identical, with 
β1=0.9684 (SE=.017) and β1=0.9782 (SE=0.0225). When added to the 
model, age was found to have a statistically significant association with 
the relation between log(NT) values and log(HI) values. The resulting 
model, log(NT) = 0.2542 + 0.9663 log(HI) – 0.0055 age (SE0=0.079, 
SE1=0.013, SE2=0.001), indicates a 0.0055 reduction in log(NT) for 
F IGURE  2 Correlation of HI and NT 
titers for all influenza A strains, H3N2 
strains, and H1N1 strains. The orange lines 
indicate perfect correlation between HI 
and NT titers. The purple line represents 
the overall smoothed mean of the data
F IGURE  3 Correlations of HI and NT titers by influenza A strain. The orange lines indicate perfect correlation between HI and NT titers. The 
purple line represents the overall smoothed mean of the data
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every year of age, adjusting for log(HI), yet starting at age 0 with a 
log(NT) of 0.25 higher than a log(HI).
Hemagglutination inhibition of ≥40 and NT of ≥20 are common-
ly used as thresholds for indication of immunity, signifying a 50% 
reduction in the risk of contracting influenza.5 Among all of the assays 
performed, 44.0% and 52.3% measured HI titers ≥40 and NT titers 
≥20, respectively (Table 1), indicating, based on these standard thresh-
olds, that there was protective immunity to about half of the influ-
enza strains performed among all study participants. Strain- specific 
HI ≥40 results ranged from 0.7% for A/California/07/2009 to 80.8% 
for A/Fujian/411/2002, and NT ≥20 results ranged from 1.3% for 
A/California/07/2009 to 84.8% for A/Wuhan/359/1995. Among 
participants aged <15 years, all (11/11) were found to have at least 
one HI titer ≥40 and at least one NT titer ≥20, whereas among adults 
(≥15 years), 2.9% (4/140) had no HI titers ≥40 and only 1/140 had no 
NT≥20.
We determined HI titer thresholds that predicted NT titer status 
using multiple titer thresholds and determined which ones maximized 
sensitivity and specificity to predict NT status. Optimal thresholds were 
found to vary by serotype and strain. Overall, an HI titer threshold of 
20 corresponded to a NT titer of 10, and an HI titer of 40 correspond-
ed to a NT titer of 20 (Table 2). These titer thresholds varied for H3N2 
and H1N1 serotypes, with higher titer thresholds for H3N2 (40 and 
40) and lower titer thresholds for H1N1 (10 and 20). Strain- specific 
HI titer thresholds varied from 10 to 80 corresponding to NT titers of 
10 and 20. We observed a mean bias between log(HI) and log(NT) of 
0.06 for all strains (Fig. S3). However, the plot of log(NT) versus bias 
demonstrated a significant negative slope of 0.23 (P<.0001), with the 
greatest magnitude in bias at high NT (Fig. S3).
Receiver operator characteristic curves comparing results of NT 
and HI assays indicated similar findings as the correlation tests (Fig. 4/
Table 2). Area under the curve (AUC) statistics indicated excellent 
accuracy of the HI test, as compared with NT as the gold standard, 
on all titer levels for both overall (all serotypes and years combined) 
and serotype- specific analysis (Table 2). Strain- specific AUCs indi-
cated at least good (>0.80) accuracy for HI tests at NT gold standard 
titers of 10 and 20 on all strains. A/Shantou/92/2009 (H1N1) and A/
California/07/2009 (H1N1) strains, which had the lowest correlation 
coefficients, produced AUC values of 84.6% and 99.5% for NT titers of 
10 and 93.5% and 99.5% for NT titers of 20, respectively.
4  | DISCUSSION
The primary goal of this study was to gain a better understanding of 
the direct comparability between hemagglutination inhibition and 
neutralization assay results for determining level of influenza immu-
nity. Overall, we found that correlation between HI and NT titers was 
high for all influenza, as well as within serotypes and among most 
specific influenza strains. While we were unable to determine a con-
sistent equivalence factor between HI and NT titers for influenza, we 
did confirm previous findings that HI titers were consistent with NT 
titers.12,16 Furthermore, we found age to be significantly associated 
with the equivalence between HI and NT, with NT more sensitive than 
TABLE  1 Hemagglutination inhibition and NT median titers and 
proportions of titers equal to or greater than the current gold 
standards of both for all twelve recently circulating influenza strains










A/Hong Kong/1/1968 40 55.00 20 59.60
A/Victoria/3/1975 40 31.10 10 36.40
A/Bangkok/1/1979 40 56.30 40 67.50
A/Beijing/353/1989 20 35.80 10 47.70
A/Wuhan/359/1995 40 69.50 80 84.80
A/Fujian/411/2002 80 80.80 80 83.40
A/Shantou/90/2003 40 62.30 40 75.50
A/Shantou/806/2005 40 57.00 40 60.30
A/Shantou/904/2008 10 28.50 10 45.00
A/Shantou/104/2005 20 42.40 20 55.00
A/Shantou/92/2009 <10 9.30 <10 11.30
A/California/07/2009 <10 0.70 <10 1.30
Total — 44.00 — 52.30
TABLE  2 Receiver operator characteristic results of comparing NT titers cutoffs with HI titers for all twelve influenza strains, H3N2 strains, 
and H1N1 strains
All Strains H3N2 H1N1
NT titer cutoff AUC (95% CI)
HI threshold 
maximizing sens/spec AUC (95% CI)
HI threshold maximizing 
sens/spec AUC (95% CI)
HI threshold 
maximizing sens/spec
10 92.8 (91.7–93.9) 20 90.7 (89.1–92.3) 40 93.5 (90.8–96.3) 10
20 93.2 (92.1–94.3) 40 90.8 (89.3–92.3) 40 96.6 (94.6–98.6) 20
40 93.9 (92.9–94.9) 40 92.1 (90.8–93.5) 40 97.6 (96.5–98.8) 20
80 93.5 (92.4–94.6) 40 91.7 (90.3–93.1) 40 97.6 (96.2–98.9) 40
160 94.0 (92.8–95.1) 80 92.3 (90.8–93.8) 80 98.3 (97.3–99.3) 40
320 95.3 (94.2–96.3) 80 93.9 (92.4–95.3) 160 98.9 (98.1–99.7) 80
640 96.8 (95.8–97.8) 160 96.1 (94.8–97.4) 160 98.8 (97.6–99.9) 80
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HI at young ages, but becoming less sensitive than HI with increasing 
age. This relationship was also demonstrated by the finding that NT 
was more sensitive than HI at higher titers, but less sensitive than 
HI at lower titers. It is unknown whether these relationships are the 
result of a more rapid decrease in detectible immunity with age by NT 
as compared to HI, or more simply caused by NT being less sensitive 
than HI at low titers and more sensitive at higher titers.
The usefulness of a generalizable equivalence factor between NT 
and HI tests is high, allowing for comparison across studies, better 
use and understanding of variable levels of immunity, and increased 
support for use of HI over NT. Although we did not identify a consis-
tent equivalence factor for influenza, we did confirm the findings of 
previous studies that HI and NT titers were similar within individuals 
overall. Complicating this comparison is our finding of the significant 
negative effect of age on the equivalence between HI and NT. While 
this effect was modest, resulting in a reduction in the equivalent NT 
titer by about 4% for every 10 years of age, because of the standard 
use of titer cut points (i.e., 20, 40, 80), this can result in full titer 
level differences between the two assays. This finding supports pre-
vious findings that titer equivalences between HI and NT for adults 
might not be the same for children.17 Furthermore, this points to the 
potential existence of an underlying biological mechanism of waning 
immunity or modified immune response as people age that differs 
between the HI and NT assays. It is not clear whether this effect is 
truly a factor of biological age or rather a factor of time since initial 
immunological challenge since these were confounded in our study. 
However, this finding further exemplifies the challenges of directly 
comparing HI and NT titer results for understanding influenza immu-
nity. More research is needed to understand these differences by 
age and how this might impact our understanding of immunity and 
vaccination.
Our results confirm previous practices of HI titer of 40 corre-
sponding with a gold standard of NT=20 for influenza overall and 
for H3N2 influenza.16 Titer threshold equivalence testing for H1N1 
influenza titers, which was determined to be 20 and 20, was limit-
ed due to minimal titer results for H1N1 influenza strains. However, 
strain- specific HI titer thresholds at which specificity and sensitivity 
were maximized for gold standard NT ≥20 varied between 20 and 80. 
As previously found by Stephenson et al.,12 producing a single effec-
tive equivalence factor, particularly one between an HI titer of 40 and 
a specific NT titer, was not possible for this study due to dependence 
on the virus–serum combination and strain- specific variation, as well 
as age.
We found that correlation between titers of different strains 
using the same assay was highest within subtypes and with close 
proximity in time of virus emergence. These findings indicate mul-
tiple possibilities, including the existence of cross- protective immu-
nity between similar strains, immune response similarity because of 
antigenically similar strains, or correlation between time of infec-
tion and titer level. We included results for both assays as they may 
characterize strain relationships differently. We are unable to deter-
mine which of these or combination thereof is the true cause of this 
correlation.
An important limitation to determining the equivalence factor in 
this study was the use of discrete titer thresholds (i.e., 20, 40. 80) and 
lack of absolute titer data. It is possible, for example, that an equiva-
lence factor found to be 2.0 (NT=20 vs HI=40) could correspond to a 
true equivalence factor closer to 1.0 if the NT mean absolute titer for 
this group is 38. Additionally, as our results confirm, we are not able 
to make any conclusions regarding the comparability or equivalence 
between HI and NT for A(H1N1)pdm09, as it is unlikely that many 
of the study subjects had been infected at the time of serum collec-
tion. While several patients have low, non- zero titers, it is possible 
these were either very recent infections, for which antibodies might 
not have fully elevated yet, or that there was cross- reactivity with a 
different influenza strain. These results are limited to application to 
seasonal influenza A strains and cannot be generalized to avian influ-
enza, influenza B, or other viruses. Furthermore, with the consistency 
issues previously observed for NT between laboratories, we cannot 
guarantee that other laboratories would observe the same consistency 
between HI and NT titers that we observed. The readout of our assay 
was based on observing cytopathic effects. Although this has found to 
be comparable with other assays, some of the variability of our results 
may be reduced with an automated readout assay.18 Finally, the rela-
tionship between correlation of titers and age could be driven by the 
fact that younger individuals had larger titers in general, thus increas-
ing the possibility of larger correlation.
Both tests are widely used to test for immunity to seasonal influen-
za A, and very few studies have directly compared their results. While 
NT remains the gold standard, HI offers several advantages that make 
a better understanding of how it correlates with NT needed. Here, 
we find overall correspondence between results, but because of the 
dependence of virus- serum interactions and an association between 
age and the HI–NT mapping, no consistent model that can be used 
across all viruses. With the broad consistency of results between HI 
and NT, the substantially increase in resources required to conduct 
NT coupled with the consistency challenges when testing at multiple 
laboratories, the HI titer might be the more appropriate assay for many 
studies.
F IGURE  4 Sensitivity and specificity of predicting NT titer of 10, 
20, and 40 using HI data for all influenza strains
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